ImmunoCellular received patent no. 7,939,090, entitled ‘System and method for the treatment of cancer, including cancers of the central nervous system,’ that covers the combination of a dendritic cell based vaccine combined with a regimen of chemotherapy enhances the clinical efficacy of treatment.
ImmunoCellular Therapeutics president and CEO Manish Singh said ICT-107, the company’s dendritic cell based vaccine candidate for the treatment of glioblastoma multiforme (GBM), elicits a cytotoxic tumor reactive response that in combination with chemotherapy might alter tumors by priming their death machinery.
ImmunoCellular Therapeutics plans to expand its Phase II trial of ICT-107 which is a double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107 to target multiple tumor associated antigens for glioblastoma.